Bayer Secures $7.25 Billion Settlement to Resolve Roundup Cancer Lawsuits

Bayer has reached a proposed $7.25 billion settlement to resolve thousands of U.S. Lawsuits alleging that its Roundup weedkiller caused cancer, particularly non-Hodgkin’s lymphoma. This move aims to definitively close a significant legal battle that has weighed on the company since its 2018 acquisition of Monsanto, the manufacturer of Roundup, for $63 billion .

Settlement Details and Timeline

The proposed settlement, announced on Tuesday, involves payments spread over up to 21 years, with the largest portion allocated to the first five years . Individuals diagnosed with non-Hodgkin’s lymphoma who were exposed to Roundup before February 17, 2026, and developed the disease before the age of sixteen are eligible to file claims for compensation . Unlike a previous agreement in 2020, this settlement intends to cover both existing and future claims related to the disease.

Previous Litigation and Costs

Bayer has already paid approximately $10 billion (roughly 205 billion Czech crowns) to settle over 130,000 Roundup-related lawsuits . Yet, around 65,000 cases remain open, and the risk of future claims persists due to the potential for cancer to manifest years after exposure.

Glyphosate and Cancer Concerns

Roundup’s active ingredient, glyphosate, was classified as “probably carcinogenic to humans” by the World Health Organization’s International Agency for Research on Cancer in 2015. However, Bayer and some regulatory agencies, including the US Environmental Protection Agency, dispute this classification, maintaining that the product is safe . Despite these claims, American juries in several states have ruled in favor of plaintiffs, awarding them billions in damages.

Supreme Court Involvement

Concurrent with the settlement proposal, Bayer awaits a decision from the U.S. Supreme Court regarding whether federal approval of Roundup can shield the company from stricter state laws concerning warning labels. The Trump administration previously supported Bayer in this case, a move that initially boosted the company’s stock .

Looking Ahead

Bayer CEO Bill Anderson anticipates that most plaintiffs will accept the proposed settlement, but acknowledges that its success hinges on resolving all outstanding disputes. This settlement represents Bayer’s attempt to close a contentious chapter that began eight years ago with the Monsanto acquisition, a deal widely considered one of the most controversial in European business history . The overall litigation liability will increase from 7.8 billion euros ($9.2 billion) to 11.8 billion euros ($13.9 billion) .